Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Zenas BioPharma, Inc. Common Stock (ZBIO) operate in?
Zenas BioPharma, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Zenas BioPharma, Inc. Common Stock (ZBIO) current stock price?
As of the latest data, Zenas BioPharma, Inc. Common Stock stock price is $27.24, with a previous close of $26.87. Zenas BioPharma, Inc. Common Stock gained $0.37 in the last trading session, representing a 1.38% increase.
What is Zenas BioPharma, Inc. Common Stock (ZBIO) current market capitalization?
Zenas BioPharma, Inc. Common Stock market cap is approximately 1.78 billion.
What is Zenas BioPharma, Inc. Common Stock (ZBIO) Earnings Per Share (EPS)?
The trailing EPS is -$9.27, and the forward EPS is -$4.66.
What is Zenas BioPharma, Inc. Common Stock (ZBIO) EBITDA?
Zenas BioPharma, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -101.04 million.
Does Zenas BioPharma, Inc. Common Stock (ZBIO) pay dividends?
No. Zenas BioPharma, Inc. Common Stock does not pay a dividend.
How did Zenas BioPharma, Inc. Common Stock (ZBIO) perform in its most recent earnings report?
In the last report (June 30, 2026), Zenas BioPharma, Inc. Common Stock posted an EPS surprise of -98.88% and a revenue surprise of -93.33%.
What is Zenas BioPharma, Inc. Common Stock (ZBIO) beta (volatility) score?
Zenas BioPharma, Inc. Common Stock has a beta of 0.027, indicating lower volatility than the overall market.
